MCID: PRS045
MIFTS: 35

Prostatic Hypertrophy malady

Summaries for Prostatic Hypertrophy

About this section


MalaCards based summary: Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostatitis and prostate cancer. An important gene associated with Prostatic Hypertrophy is ACPP (acid phosphatase, prostate), and among its related pathways are Glioma and Regulation of Androgen receptor activity. The drugs prazosin and finasteride and the compounds provenge and estracyt have been mentioned in the context of this disorder. Affiliated tissues include prostate, heart and kidney.

Aliases & Classifications for Prostatic Hypertrophy

About this section

Prostatic Hypertrophy, Aliases & Descriptions:

Name: Prostatic Hypertrophy 9 11 60
Benign Prostatic Hypertrophy 60
 
Prostatic Hyperplasia 60


External Ids:

Disease Ontology9 DOID:11132

Related Diseases for Prostatic Hypertrophy

About this section

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to prostatic hypertrophy

Symptoms for Prostatic Hypertrophy

About this section

Drugs & Therapeutics for Prostatic Hypertrophy

About this section

Genetic Tests for Prostatic Hypertrophy

About this section

Anatomical Context for Prostatic Hypertrophy

About this section

MalaCards organs/tissues related to Prostatic Hypertrophy:

31
Prostate, Heart, Kidney, Breast, Bone, Smooth muscle, Colon, Appendix

Animal Models for Prostatic Hypertrophy or affiliated genes

About this section

Publications for Prostatic Hypertrophy

About this section

Articles related to Prostatic Hypertrophy:

(show top 50)    (show all 522)
idTitleAuthorsYear
1
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. (24892642)
2014
2
Tadalafil and benign prostatic hypertrophy. Too risky. (24860894)
2014
3
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. (22123290)
2012
4
Testosterone levels in benign prostatic hypertrophy and prostate cancer. (18362481)
2008
5
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study? (16412808)
2006
6
Consensus conference about imaging of Benign Prostatic Hypertrophy. (16200040)
2005
7
Quality improvement activities in prostatectomy for benign prostatic hypertrophy. (12698520)
2003
8
Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy. (12534901)
2002
9
Ammonium-chloride-induced prostatic hypertrophy in vitro: urinary ammonia as a potential risk factor for benign prostatic hyperplasia. (10550527)
1999
10
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. (9393292)
1997
11
Detection of bladder tumor by urine cytology in cases of prostatic hypertrophy. (8989544)
1996
12
Laser ablation of prostatic hypertrophy. (7544883)
1995
13
Microwave hyperthermia in benign prostatic hypertrophy: a controlled clinical trial. (7544207)
1995
14
Objective noninvasive evaluation of benign prostatic hypertrophy. (7535622)
1995
15
Short-term oral treatment of canine benign prostatic hypertrophy with chlormadinone acetate. (7538794)
1995
16
Benign prostatic hypertrophy. Options for management. (7518555)
1994
17
New treatments for benign prostatic hypertrophy. (7527259)
1994
18
Technology briefs from the Conseil d'Evaluation des Technologies de la SantAc du QuAcbec (CETS). Diathermy and balloon dialatation treatment of benign prostatic hypertrophy. (7507097)
1993
19
Minimally invasive therapy in bladder outflow obstruction due to benign prostatic hypertrophy. A review of prostatic balloon dilatation and stenting. (7689316)
1993
20
Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy. (7679580)
1993
21
Urinary flow rate in benign prostatic hypertrophy in relation to the degree of obstruction of the vesical outlet. (1373665)
1992
22
Subjective and clinical results after transurethral resection and suprapubic prostatectomy in benign prostatic hypertrophy. (1726084)
1991
23
Dynamics of micturition in benign prostatic hypertrophy patients with compensated obstruction of the vesical outlet: a denervation supersensitivity-related energy-saving mechanism. (1719245)
1991
24
Endocrine treatment of benign prostatic hypertrophy: current concepts. (1702565)
1991
25
Prazosin: an evaluation of its clinical efficacy and safety in the treatment of benign prostatic hypertrophy. (1690475)
1990
26
Re: Bladder outflow tract obstruction and urinary retention from benign prostatic hypertrophy treated by balloon dilatation. (1699630)
1990
27
The effect of bromocriptine in benign prostatic hypertrophy and vesicosphincteric dynamics. (2444307)
1987
28
Development of benign prostatic hypertrophy estimated from ultrasonic measurement with long-term follow up. (2437669)
1987
29
Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection. (2436203)
1987
30
Specific binding of [3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH). (88546)
1979
31
Serum dihydrotestosterone in patients with benign prostatic hypertrophy. (73397)
1977
32
Using antiandrogen therapy in benign prostatic hypertrophy. (66171)
1977
33
The effect of bromocriptine in patients with benign prostatic hypertrophy. (57815)
1976
34
Correlations between clinical findings and urinary flow rate in benign prostatic hypertrophy. (61184)
1976
35
Intracellular localisation of 5alpha-dihydrotestosterone in human benign prostatic hypertrophy. (63340)
1976
36
Urinary flow rate in benign prostatic hypertrophy. (56317)
1976
37
The effect of a 6FG urethral catheter on urinary flow in benign prostatic hypertrophy. (61185)
1976
38
In vivo uptake and metabolism of 3-h-5alpha-androstane-3alpha,17beta-diol and of 3-h-5alpha-androstane-3beta,17beta-diol by human prostatic hypertrophy. (49141)
1975
39
Flat epithelial changes in the urinary bladder in patients with prostatic hypertrophy. (4118752)
1972
40
Therapy with progestational agents in advanced benign prostatic hypertrophy. (4187537)
1969
41
Treatment of benign prostatic hypertrophy with progestational agents: a preliminary report. (4172531)
1968
42
Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. (4143704)
1966
43
TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION. (14304354)
1965
44
VOIDING PRESSURE AND URINARY FLOW IN PROSTATIC HYPERTROPHY AND IN NEUROGENIC BLADDER DISORDERS. (14227133)
1964
45
Prostatic hypertrophy in Indonesia. (13919435)
1962
46
Sex chromatin in cells of prostatic hypertrophy and prostatic cancer. (13364266)
1956
47
Benign prostatic hypertrophy. (13346266)
1956
48
Transurethral, perineal, and retropubic prostatectomy; an analysis of 300 operations performed for the correction of benign prostatic hypertrophy. (14836118)
1951
49
Prostatic hypertrophy. (18148544)
1949
50
Benign prostatic hypertrophy, with obstruction. (18899249)
1948

Variations for Prostatic Hypertrophy

About this section

Expression for genes affiliated with Prostatic Hypertrophy

About this section
Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for genes affiliated with Prostatic Hypertrophy

About this section

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
Signaling Pathways in Glioblastoma36
9.4FGF8, KLK3
29.3KLK3, SRY

Compounds for genes affiliated with Prostatic Hypertrophy

About this section
Sources:
43Novoseek, 28IUPHAR, 12DrugBank, 59Tocris Bioscience, 24HMDB
See all sources

Compounds related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 29)
idCompoundScoreTop Affiliating Genes
1provenge439.9KLK3, ACPP
2estracyt439.9ACPP, KLK3
3chlormadinone acetate439.9ACPP, KLK3
4estramustine phosphate439.9ACPP, KLK3
5goserelin43 28 1211.8ACPP, KLK3
6nilutamide43 59 28 1212.8ACPP, KLK3
7buserelin43 28 1211.8ACPP, KLK3
8estramustine43 1210.8ACPP, KLK3
9finasteride43 59 24 1212.8KLK3, ACPP
10dtpa439.8KLK3, ACPP
11cyproteroneacetate439.8ACPP, KLK3
12flutamide43 59 1211.8KLK3, ACPP
13bicalutamide43 59 1211.8ACPP, KLK3
14diethylstilbestrol43 28 1211.7KLK3, ACPP
15dehydroepiandrosterone sulfate439.7KLK3, ACPP
16dhea439.7KLK3, ACPP
17gnrh439.5ACPP, KLK3
18biotin43 24 1211.4KLK3, SRY
19guanine43 24 1211.4KLK3, SRY
20suramin43 28 1211.3FGF8, KLK3, ACPP
21deoxyribonucleic acid439.3KLK3, ACPP, SRY
22dihydrotestosterone43 28 24 1212.2KLK3, ACPP, SRY
23vitamin d439.2KLK3, ACPP
24estradiol43 24 1211.2KLK3, ACPP, SRY
25steroid439.1SRY, ACPP, KLK3
26polysaccharide439.0KLK3, LGALS8
27zinc43 2410.0FGF8, ACPP, SRY
28serine438.9KLK3, ACPP, SRY
29testosterone43 59 24 1211.7SRY, ACPP, KLK3, FGF8

GO Terms for genes affiliated with Prostatic Hypertrophy

About this section

Cellular components related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:00056158.7FGF8, ACPP, LGALS8

Products for genes affiliated with Prostatic Hypertrophy

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Prostatic Hypertrophy

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet